Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts. more
Time Frame | BFRI | Sector | S&P500 |
---|---|---|---|
1-Week Return | -7.69% | -2.12% | -3% |
1-Month Return | 25.46% | -3.42% | -0.73% |
3-Month Return | -23.55% | -11.13% | 2.87% |
6-Month Return | -5% | -5.74% | 7.17% |
1-Year Return | -71.22% | 3.97% | 25.31% |
3-Year Return | -99.36% | 1.05% | 28.38% |
5-Year Return | -98.89% | 34.37% | 81.89% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 26.18M | 18.85M | 24.10M | 28.67M | 34.07M | [{"date":"2019-12-31","value":76.84,"profit":true},{"date":"2020-12-31","value":55.32,"profit":true},{"date":"2021-12-31","value":70.73,"profit":true},{"date":"2022-12-31","value":84.16,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 12.41M | 9.07M | 12.74M | 15.19M | 17.44M | [{"date":"2019-12-31","value":71.13,"profit":true},{"date":"2020-12-31","value":51.97,"profit":true},{"date":"2021-12-31","value":73.05,"profit":true},{"date":"2022-12-31","value":87.05,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 13.77M | 9.78M | 11.36M | 13.49M | 16.63M | [{"date":"2019-12-31","value":82.84,"profit":true},{"date":"2020-12-31","value":58.84,"profit":true},{"date":"2021-12-31","value":68.31,"profit":true},{"date":"2022-12-31","value":81.13,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | 52.61% | 51.90% | 47.13% | 47.04% | 48.80% | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":98.66,"profit":true},{"date":"2021-12-31","value":89.59,"profit":true},{"date":"2022-12-31","value":89.42,"profit":true},{"date":"2023-12-31","value":92.77,"profit":true}] |
Operating Expenses | 28.70M | 18.12M | 37.21M | 35.87M | 39.30M | [{"date":"2019-12-31","value":73.01,"profit":true},{"date":"2020-12-31","value":46.09,"profit":true},{"date":"2021-12-31","value":94.67,"profit":true},{"date":"2022-12-31","value":91.26,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (14.92M) | (8.33M) | (25.85M) | (22.38M) | (22.68M) | [{"date":"2019-12-31","value":-1492200000,"profit":false},{"date":"2020-12-31","value":-833400000,"profit":false},{"date":"2021-12-31","value":-2585100000,"profit":false},{"date":"2022-12-31","value":-2238100000,"profit":false},{"date":"2023-12-31","value":-2267700000,"profit":false}] |
Total Non-Operating Income/Expense | 1.84M | (5.46M) | (12.80M) | 17.78M | 2.27M | [{"date":"2019-12-31","value":10.34,"profit":true},{"date":"2020-12-31","value":-30.7,"profit":false},{"date":"2021-12-31","value":-72,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":12.76,"profit":true}] |
Pre-Tax Income | (10.95M) | (10.92M) | (37.66M) | (608.00K) | (20.12M) | [{"date":"2019-12-31","value":-1094900000,"profit":false},{"date":"2020-12-31","value":-1092300000,"profit":false},{"date":"2021-12-31","value":-3765700000,"profit":false},{"date":"2022-12-31","value":-60800000,"profit":false},{"date":"2023-12-31","value":-2011700000,"profit":false}] |
Income Taxes | 33.00K | 64.00K | 56.00K | 32.00K | 14.00K | [{"date":"2019-12-31","value":51.56,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":87.5,"profit":true},{"date":"2022-12-31","value":50,"profit":true},{"date":"2023-12-31","value":21.88,"profit":true}] |
Income After Taxes | (10.98M) | (10.99M) | (37.71M) | (640.00K) | (20.13M) | [{"date":"2019-12-31","value":-1098200000,"profit":false},{"date":"2020-12-31","value":-1098700000,"profit":false},{"date":"2021-12-31","value":-3771300000,"profit":false},{"date":"2022-12-31","value":-64000000,"profit":false},{"date":"2023-12-31","value":-2013100000,"profit":false}] |
Income From Continuous Operations | (10.98M) | (10.99M) | (37.71M) | (640.00K) | (26.44M) | [{"date":"2019-12-31","value":-1098200000,"profit":false},{"date":"2020-12-31","value":-1098700000,"profit":false},{"date":"2021-12-31","value":-3771300000,"profit":false},{"date":"2022-12-31","value":-64000000,"profit":false},{"date":"2023-12-31","value":-2644200000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (10.98M) | (10.99M) | (37.71M) | (640.00K) | (20.13M) | [{"date":"2019-12-31","value":-1098200000,"profit":false},{"date":"2020-12-31","value":-1098700000,"profit":false},{"date":"2021-12-31","value":-3771300000,"profit":false},{"date":"2022-12-31","value":-64000000,"profit":false},{"date":"2023-12-31","value":-2013100000,"profit":false}] |
EPS (Diluted) | - | - | (3.52) | (0.45) | (10.50) | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-352,"profit":false},{"date":"2022-12-31","value":-45,"profit":false},{"date":"2023-12-31","value":-1050,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
BFRI | |
---|---|
Cash Ratio | 0.26 |
Current Ratio | 1.53 |
Quick Ratio | 0.94 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
BFRI | |
---|---|
ROA (LTM) | -40.24% |
ROE (LTM) | -149.41% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
BFRI | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.70 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.30 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
BFRI | |
---|---|
Trailing PE | 0.84 |
Forward PE | NM |
P/S (TTM) | 0.22 |
P/B | 1.39 |
Price/FCF | NM |
EV/R | 0.16 |
EV/Ebitda | NM |
Biofrontera Inc (BFRI) share price today is $0.9785
Yes, Indians can buy shares of Biofrontera Inc (BFRI) on Vested. To buy Biofrontera Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in BFRI stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Biofrontera Inc (BFRI) via the Vested app. You can start investing in Biofrontera Inc (BFRI) with a minimum investment of $1.
You can invest in shares of Biofrontera Inc (BFRI) via Vested in three simple steps:
The 52-week high price of Biofrontera Inc (BFRI) is $3.9. The 52-week low price of Biofrontera Inc (BFRI) is $0.61.
The price-to-earnings (P/E) ratio of Biofrontera Inc (BFRI) is 0.8381
The price-to-book (P/B) ratio of Biofrontera Inc (BFRI) is 1.39
The dividend yield of Biofrontera Inc (BFRI) is 0.00%
The market capitalization of Biofrontera Inc (BFRI) is $7.53M
The stock symbol (or ticker) of Biofrontera Inc is BFRI